Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial. (November 2014)

• Record Type: Journal Article
• Authors: Bjerre, Mette; Hilden, Jørgen; Kastrup, Jens; Skoog, Maria; Hansen, Jørgen F.; Kolmos, Hans J.; Jensen, Gorm B.; Kjøller, Erik; Winkel, Per; Flyvbjerg, Allan; Gluud, Christian; The Claricor Trial Group
• Is Part Of: Scandinavian journal of clinical & laboratory investigation. Volume 74:Number 8(2014)
• Page Start: 657
• Page End: 664
• Publication Date: 2014-11
• Subjects: Clinical biochemistry -- Periodicals; Physiology, Pathological -- Periodicals; Physiology, Experimental -- Periodicals; Medicine -- Research -- Periodicals; Clinical medicine -- Periodicals; 616.0072
• DOI: 10.3109/00365513.2014.930510
• Languages: English
• ISSNs: 0036-5513

Abstract

<abstract> <title>Abstract</title> <p> <bold> <italic>Objectives.</italic> </bold> To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD). <bold><italic>Methods.</italic></bold> Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality. <bold><italic>Results.</italic></bold> OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, <italic>p</italic> < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log<sub>10</sub> unit increase] 6.1 [95% CI 2.4–15.6, <italic>p = </italic>0.0001]) and HR 6.5 [95% CI 3.4–12.5, <italic>p</italic> < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6–3.9, <italic>p</italic> < 0.0001]). <bold><italic>Conclusions.</italic></bold> Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.</p> </abstract>